Breaking News

Pentarlandir Proves Effective Against COVID-19 Variants in Preclinical Studies

Costs for the drug are expected to be significantly lower than for Pfizer’s Paxlovid.

Author Image

By: Charlie Sternberg

Associate Editor

SyneuRx International’s investigational oral SARS-CoV-2 (COVID-19) anti-viral drug candidate Pentarlandir has successfully demonstrated effectiveness against both the Omicron and Delta variants of the virus  in its preclinical studies. Pentarlandir is currently in the final stage of a Phase II US-FDA trial (Phase III is scheduled to begin in 2022).    Designed as an early-stage COVID-19 treatment, Pentarlandir is given by mouth to patients suffering either from early-stage ‘breakthrough&#8...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters